In this article, we will look at the 10 Best Performing Healthcare Stocks So Far in 2026.
On May 4, Dina DiLorenzo, Guggenheim Investments president, joins ‘Power Lunch’ to discuss the market’s recent resilience, credit markets, and much more.
She was of the view that the backdrop at present is featuring geopolitical tensions, Fed policy uncertainty, inflation concerns, and still, it is incredible that the stock market is at record highs. She is looking at it from the perspective of strong balance sheets, strong corporate earnings, strong AI spending, and forward-looking pricing, probably already embedded in the markets.
READ ALSO: 10 Best Performing Small Cap Stocks So Far in 2026 AND 10 Best Medical Device Stocks to Invest In Right Now.
DiLorenzo was further of the view that AI is playing a role here in terms of emotional volatility: it is mitigating some of that emotional volatility, and we are seeing that these AI products are really coming in, with data processing and investment workflows reflecting it. She also said that, for her, as a fixed-income global asset manager with a focus on public and private credit, she does see some volatility. She considers this a yellow flag as the equity markets follow, and that is why she is being “super cautious”.
With these broader market trends in view, let’s look at the best performing healthcare stocks so far in 2026.
A healthcare professional in a meeting with a patient discussing care options using digital technology.
Our Methodology
We used the Finviz stock screener to identify the best healthcare stocks that have exhibited strong share price performance YTD, and limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds, as of Q4 2025. The stocks are arranged in ascending order of YTD performance.
Note: All data was recorded on May 4.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
10 Best Performing Healthcare Stocks So Far in 2026
10. CG Oncology, Inc. (NASDAQ:CGON)
YTD Share Price Gain: 60.74%
CG Oncology, Inc. (NASDAQ:CGON) is one of the best performing healthcare stocks so far in 2026. RBC Capital lifted the price target on CG Oncology, Inc. (NASDAQ:CGON) to $79 from $73 on April 27, reaffirming an Outperform rating on the shares. The firm told investors in a research note that one of the most complex catalysts in the firm’s universe is PIVOT-006, given the recent run-up and future catalyst path from a tactical perspective, as well as the limited data from which to base readout expectations on a fundamental basis. The firm added that it anticipates data from the trial in early June and expects to deliver a 40% risk reduction, driving 20% upside in shares.
CG Oncology, Inc. (NASDAQ:CGON) also received a rating update from BofA on April 14. The firm lifted the price target on the stock to $84 from $72, maintaining a Buy rating on the shares. It stated that shares have run up 62% year-to-date with the acceleration of the timeline for PIVOT-006 IR NMIBC data, adding that the BofA is “still bullish at current levels” and sees “more room to run.”
CG Oncology, Inc. (NASDAQ:CGON) is a clinical biopharmaceutical company that develops and commercializes bladder-sparing therapeutic patients afflicted with bladder cancer. The company offers cretostimogene, which is a product initially in clinical development to treat patients with Non-Muscle Invasive Bladder Cancer (NMIBC).
9. Twist Bioscience Corporation (NASDAQ:TWST)
YTD Share Price Gain: 75.05%
Twist Bioscience Corporation (NASDAQ:TWST) is one of the best performing healthcare stocks so far in 2026. Twist Bioscience Corporation (NASDAQ:TWST) announced its fiscal Q2 2026 financial results and business highlights on May 4, reporting solid performance in the first half of 2026. It ended fiscal Q2 with its 13th consecutive quarter of growth, with total revenue for the quarter reaching $110.7 million, up 19% compared to $92.8 million for the same period last year. Cost of revenues for the quarter rose to $53.6 million, up from $46.8 million in fiscal Q2 2025, while gross margin increased to 51.6% compared to 49.6% for the prior year period.
Twist Bioscience Corporation (NASDAQ:TWST) further reported that research and development expenses for fiscal Q2 2025 decreased to $19.7 million compared to $23.9 million for the same period of fiscal 2025. The company shipped products to approximately 2,583 customers in the quarter, up from approximately 2,431 in the same period of fiscal 2025.
Twist Bioscience Corporation (NASDAQ:TWST) is involved in the development of a proprietary semiconductor-based synthetic DNA manufacturing process. The company’s operations are divided into the following geographical segments: Americas, EMEA, and APAC.
Hedge Fund Resource Center